natgillin/translations-raw huggingface dataset:
In another example, the third user marking cell may be detected based at least in part upon interpolation between: (a) the position of the detected first user marking cell; and (b) the position of the detected second user marking cell. 
Postupak u skladu s patentnim zahtjevom 6, naznačen time što se treću ćeliju za korisničku oznaku detektira na temelju u najmanju ruku dijelom interpolacije između: (a) položaja detektirane prve ćelije za korisničku oznaku; i (b) položaja detektirane druge ćelije za korisničku oznaku.
In addition, compounds of formula (III) wherein R3 represents a fluorine atom may be obtained by analogy to the method described in Tetrahedron Letters, Vol. 
Uz to, spojeve formule (III), gdje R3 predstavlja atom fluora, može se dobiti postupkom analognim onom opisanom u Tetrahedron Letters, sv.
A recombinant nucleic acid operatively linked to expression control sequences, said nucleic acid comprising a nucleic acid sequence selected from the group consisting of: 
laki lanac koji sadrži aminokiselinsku sekvencu izabranu iz grupe koja se sastoji od SEQ ID NO: 121, 122, 123, 124, 125, 126, 127, 128, 129 i fragmenta iste.
In some embodiments, the composition may preferably be a lyophilisate. In some embodiments, the composition of the invention is for use in treating diarrhea and/or constipation in a subject having an increased level of hydrogen in their breath relative to a healthy subject. 
(c) u postupku liječenja konstipacije pri čemu subjekt ima konstipaciju bez dijareje Kompozicija za upotrebu prema bilo kojem prethodnom zahtjevu, gdje subjekt ima dodatno abdominalnu bol i/ili krvarenje i/ili gdje subjekt zma povećanu razinu vodika u njegovom dahu, u odnosu na zdravi subjekt.
A method for immunizing a patient against influenza virus, comprising steps of (i) administering to a subject an immunogenic composition comprising hemagglutinin antigen from a first clade of H5 influenza A virus, and later (ii) administering to the subject an immunogenic composition comprising hemagglutinin antigen from a second clade of H5 influenza A virus, wherein the first and second clades are different from each other, and wherein one or both of the immunogenic compositions includes influenza A virus neuraminidase antigen. 
Imunogeni pripravak koji sadrži antigen hemaglutinina iz prvog klada H5 virusa influence A, naznačen time da je za uporabu u postupku imunizacije subjekta protiv virusa influence koji sadrži korake (i) davanja subjektu imunogenog pripravka koji sadrži antigen hemaglutinina iz prvog klada H5 virusa influence A, te zatim (11) davanja subjektu imunogenog pripravka koji sadrži antigen hemaglutinina iz drugog klada H5 virusa influence A, pri čemu su prvi i drugi klad međusobno različiti, te gdje:
The compound according to claim 1 which is 6-{4-[5-Cyclopropyl-3-(2,6-dichloro-phenyl)-isoxazol-4-ylmethoxy]-piperidin-1-yl}-1-methyl-1H-indole-3-carboxylic acid or a pharmaceutically acceptable salt or enantiomer thereof. 
Spoj u skladu s patentni zahtjev 1, naznačen time što je 6-{4-[5-ciklopropil-3-(2,6-diklorfenil)izoksazol-4-ilmetoksi]piperidin-1-il}-1-metil-1H-indol-3-karboksilna kiselina [image] ili njezina farmaceutski prihvatljiva sol ili enantiomer.
A plate 80 immediately above the plate 70 has a lower flange 82 (similar to the flange 74 of plate 70). A baffle 84 depends downwardly from the flange 82 (when the plate 80 is moving along the vertical path), and covers the space between the adjacent flanges 72, 82 of the plates 70, 80 . 
Sušilica prema patentnom zahtjevu 4 kod koje su ploče (70, 80) sa otvorima konstruirane sa odbojnim pločama koje su nagnute prema dole preko otvora u pločama (70, 80) 1 u vertikalnoj putanji kada se ploče (70, 80) pomiču prema dole duž vertikalne putanje.
The method for preparing a diol as claimed in claim 1 or 2, characterized in that the sugar is selected from one or more of five-carbon monosaccharides, disaccharides and oligosaccharides, six-carbon monosaccharides, disaccharides and oligosaccharides, soluble five-carbon polysaccharides, and soluble six-carbon polysaccharides. 
Postupak za pripremu diola prema patentnom zahtjevu 1, naznačen time što je šećer odabran između jednog ili više monosaharida sa pet ugljika, disaharida i oligosaharida, monosaharida sa šest ugljika, disaharida i oligosaharida, topivog polisaharida sa pet ugljika i topivog polisaharida sa šest ugljika.
A compound for use according to claim 18 wherein the disorder mediated by inappropriate PI3-kinase activity is a respiratory disease, a viral infection, a non-viral respiratory infection, an allergic disease, an autoimmune disease, an inflammatory disorder, a cardiovascular disease, a hematologic malignancy, a neurodegenerative disease, pancreatitis, multiorgan failure, kidney disease, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection, lung injury, or pain. 
Kombinacija namijenjena upotrebi u skladu s patentnim zahtjevom 11, naznačena time što je poremećaj uzrokovan neodgovarajućom aktivnošću P13-kinaze respiratorna bolest, virusna infekcija, nevirusna respiratorna infekcija, alergijska bolest, autoimuna bolest, upalni poremećaj, kardiovaskularna bolest, hematološki zloćudni tumor, neurodegenerativna bolest, pankreatitis, multiorganska insuficijencija, bolest bubrega, agregacija trombocita, rak, pokretljivost sperme, odbacivanje transplantata, odbacivanje presatka, ozljeda pluća, ili bol.
Atomiser according to claim 9 and 11, characterised in that the locking device (78) has a control part (45), which in particular can be moved peripherally in relation to the longitudinal, rotational or movement axis of the atomiser (1), for operation or movement of the lock part (41). 
Raspršivač prema zahtjevima 9 i 11, naznačen time, da zaporni uređaj (78) ima upravljač (45) koji se posebno može pokretati periferno u odnosu na uzdužnu, rotacijsku ili pokretnu os raspršivača (1), za rad ili pokretanje ključa
The method comprising the following steps: 
što je definirano u patentnom zahtjevu 1, sadržava sljedeće korake:
The formulation according to claim 8, wherein the antibody is the humanized anti-IL-6 receptor antibody MRA, the concentration of arginine is 50 to 700 mM, the concentration of methionine is 10 to 100 mM, the amount of polysorbate 80 as the surfactant is 0.005 to 3% (w/v), the concentration of the histidine buffer solution is 5 to 100 mM, and the concentration of the antibody is 100 to 300 mg/ml. 
Formulacija prema zahtjevu 8, naznačena time da protutijelo je humanizirano anti-IL-6 receptorsko protutijelo MRA, koncentracija arginina je 50 do 700 mM, koncentracija metionina je 10 do 100 mM, količina polisorbata 80 kao surfaktanta je 0.005 do 3% (€/v), koncentracija histidinske puferske otopine je 5 do 100 mM, a koncentracija protutijela je 100 do 300 mg/ml.
The process of claim 1, further comprising co-processing a non-renewable hydrocarbon feedstock with the reaction effluent in the hydrotreating step. The process of claim 1, further comprising fractionating the hydrotreated effluent to recover one or more hydrocarbon fractions boiling in a range of naphtha, diesel, or jet fuel. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da nadalje obuhvaća frakcioniranje hidroobrađenog tekućeg otpada (34; 84) da se dobije jedna ili više frakcija ugljikovodika s vrelištima u području nafte (38), dizela (41) ili mlaznog goriva (40).
the cap (116) has a ring shaped cross-section and is sized and shaped so as to be connectable to the base (134) around the second end of the base such that the port is accessible through the cap when the cap is connected to the base; and 
Uređaj prema zahtjevu 1, naznačen time, da: baza obuhvaća navoje na drugoj strani baze; i kapica je djelotvorno uređena da se navija na navoje, kako bi se kapica učvrstila za bazu.
The method according to claim 1, further comprising applying a powder based balancing layer (4) comprising wood fibers and a thermosetting resin on a rear side of the core (3). 
Postupak prema zahtjevu 1, naznačen time što dalje obuhvaća nanošenje balansirajućeg sloja temeljenog na prahu (4) koji sadrži drvena vlakna i termoreaktivnu smolu na stražnju stranu jezgre (3).
In yet another aspect, the Bacillus coagulans of the invention survives storage (shelf-life) in food bars for at least about 6 to at least about 18 months. 
Pekarska kompozicija iz patentnog zahtjeva 11, gdje Bacillus coagulans spore ostaju žive i sposobne za klijanje tokom najmanje oko 6 do najmanje oko 18 mjeseci.
A vector comprising the nucleic acid sequence of claim 13 . 
Vektor, koji sadrži sekvencu nukleinske kiseline sukladno patentnom zahtjevu 11.
A compound of formula I, its tautomeric forms, its stereoisomers, and its pharmaceutically acceptable salts, wherein, in the compound of formula I, 
Spoj formule I, njegovi tautomerni oblici, njegovi stereoizomeri i njegove farmaceutski prihvatljive soli, [image] naznačen time što, u spoju formule I, Z je izabran iz grupe koja se sastoji od -S-, -O- i -N(Ra)-;
98.3 After filtration 
98.3 Poslije filtracije
When a compound of the formula (I) contains a free base such salts are prepared in a conventional manner by treating a solution or suspension of a free base of the formula (I) with a chemical equivalent of a pharmaceutically acceptable acid. 
Kao spoj formule (I) sadrži slobodnu bazu te se soli pripravljaju na uobičajeni način tretiranjem otopine ili suspenzije slobodne baze formule (1) kemijskim ekvivalentom farmaceutski prihvatljive kiseline.
In one embodiment of the methods provided above, culturing the one or more cells comprises batch cultivation of the cells. In one embodiment of the methods provided above, culturing the one or more cells comprises continuous cultivation of the cells. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što se uzgoj jedne ili više stanica sastoji u šaržnom uzgoju stanica ili u kontinuiranom uzgoju stanica.
The fans are operated to draw air over the radiator elements to heat the air and distribute the heated air inside the mushroom growing shed 3 . 
Postupak prema zahtjevu 5 gdje se zagrijana tekućina dovodi do radijatora koji se nalazi unutar nastambe za perad.
a contiguous sequence of the human λ light chain locus that spans from hVλ5-52 through hVλ1-40 and a contiguous sequence of the human λ light chain locus that spans from hVλ3-29 through hVλ3-1. 
graničnu sekvencu lokusa humanog lakog lanca λ koja se proteže od hVλ5- 52 do hVλ1-40 i graničnu sekvencu lokusa humanog lakog lanca λ koja se proteže od hVλ3-29 do hVλ3-1.
Use of a compound for the manufacture of a medicament for the treatment of a bacterial infection, said compound being a compound of Formula (Ia) and (Ib) a pharmaceutically acceptable acid or base addition salt thereof, a quaternary amine thereof, a stereochemically isomeric form thereof, a tautomeric form thereof or a N -oxide form thereof, wherein 
Uporaba spoja za proizvodnju lijeka za liječenje bakterijske infekcije, a navedeni spoj je spoj sa formulom (Ia) i (Ib) [image] [image] njegova farmaceutski prihvatljiva kisela ili bazna adicijska sol, njegov kvaternarni amin, njegov stereokemijski izomerni oblik, njegov tautomerni oblik ili njegov N-oksid, naznačen time da
The reaction is suitably performed in the presence of a suitable base. 
Reakcija se poželjno provodi u prisutnosti prikladne baze.
wherein X is selected from the group consisting of Glu, Lys, and Cys; and wherein the side chain of X is conjugated to a lipophilic substituent having the formula: Z1, wherein Z1 is a lipophilic moiety conjugated directly to the side chain of X; or 
X17je X; pri čemu je X odabran iz skupine koju čine Glu, Lys i Cys; i gdje je bočni lanac od najmanje jednog ostatka X konjugiran na lipofilni supstituent koji ima formulu: (i) Z!', gdje Z! je lipofilni dio skupine konjugiran izravno na bočni lanac od X; ili
9 shows a cross-sectional view of the extraction module when in an intermediate state. 
prikazuje pogled na poprečni presjek modula za ekstrakciju kada je u svojem otvorenom položaju.
A compound of Formula (I) according to claim 1 wherein R4 is hydrogen, the R3 in meta position is hydrogen and the R3 in ortho position is selected from the group consisting of halogen, or C1-C4 alkyl, and R5 is an heterocyclic ring selected from pyrimidin-2-yl, pyridin-2-yl or pyrazin-2-yl, optionally substituted with halogen. 
Spoj formule (T) prema patentnim zahtjevima 1-4 naznačeno time da je R* vodik, R* u meta-položaju jest vodik a R? u ortho-položaju odabran je iz skupine koju čine halogen, ili C;-C, alkil, a R? je heterociklički prsten odabran od pirimidin-2-il, piridin-2-11l ili pirazin-2-1l, koji može biti supstituiran halogenom.
p is an integer ranging from 0 to 2; 
p je cijeli broj u opsegu od 0 do 2;
Normally, a filling medium will be used that is low in viscosity and/or has high volatility in order to allow processing at relatively low temperatures. 
Normalno, da bi se moglo raditi pri relativno niskim temperaturama upotrijebit će se ono punilo koje ima nisku viskoznost i/ili koje ima visoku hlapljivost.
The heteromolecular metal complex according to claim 1, wherein organic molecule A is a humic acid extracted from at least one of a sedimentary organic material and fresh vegetable compost. 
Heteromolekularni metalni kompleksi (kelati) otkriveni u zahtjevima 1 do 6, naznačeni time što je molekula A huminska kiselina izlučena iz jednog ili više sedimentarnih organskih materijala (leonardita, lignita ili treseta) ili/i svježeg povrtnog komposta.
In further embodiments, the present disclosure is directed to a method for reducing nocturnal urine volume in a patient in need thereof comprising: administering to the patient prior to bedtime an orodispersible dose of desmopressin of 10 ug, wherein the dose is measured as the free base of desmopressin and the dose taken over a treatment period reduces the patient's nocturnal urine volume. 
HR P20191854 T1 PATENTNI ZAHTJEVI Pripravak koji sadrži dezmopresin za uporabu u liječenju nokturije ili noćne poliurije za povećanje početnog razdoblja nesmetanog spavanja kod ženskog pacijenta kojem je potreban, naznačen time da pripravak sadrži orodisperzibilnu dozu od 25 mikrograma dezmopresina pri čemu se doza mjeri kao slobodna baza dezmopresina i koja se daje pacijentu prije spavanja.
A compound of formula (B1), (B2), (B3), or (B5) as defined in claims 6, 7, 8, and 9. 
Spoj s formulom (B1), (B2), (B3), ili (B5) kako je definirano u zahtjevima 6, 7, 8,19.
The method of claim 1, wherein the carbonylation product stream is provided to the second reaction zone as a gaseous stream, preferably wherein the carbonylation product stream comprises a mixture of beta propiolactone and carbon monoxide, or wherein the carbonylation product stream is essentially free of unreacted ethylene oxide. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se struju produkta karboniliranja dovodi u drugo područje reakcije u obliku plinovite struje, izborno gdje struja produkta karboniliranja sadrži smjesu fpropiolaktona s ugljičnim monoksidom, ili gdje struja produkta karboniliranja uglavnom ne sadrži neizreagirani etilen-oksid.
Pharmaceutical composition comprising at least one human Tr1 cell population directed against a joint-associated antigen in combination with one or more pharmaceutically acceptable carrier. 
Smjesa koja obuhvaća najmanje jednu populaciju ljudskih Tr1 stanica koje djeluju protiv kolagena tipa II za upotrebu u liječenju artritičnih stanja u potrebitih pacijenata.
The method according to claim 1, wherein said condition is selected from the group consisting of atherosclerosis, inflammation of the eye including uveitis, iritis, iridocyclitis, alcoholic hepatitis, allograft transplantation, xenograft transplantation, glomerulonephritis, reperfusion injury and acute inflammatory conditions following myocardial infarction and stroke. 
Farmaceutski sastav u skladu s patentnim zahtjevom 12, pri čemu je navedena upalna bolest odabrana 12 grupe koja se sastoji od ateroskleroze, upale oka uključujući uveitis, iritis, iridociklitis, alkoholnog hepatitisa, transplantacije alografta, transplantacije ksenografta, glomerulonefritisa, reperfuzijske ozljede 1 akutnih upalnih stanja nakon infarkta miokarda i moždanog udara.
A first composition comprising a compound of formula (1) is 1,1'-[1,4-phenylene-bis-(methylene)-bis-1,4,8,11-tetraazacyclotetradecane (AMD3100); and a second composition comprising a peptide which is a covalent conjugate between a G-CSF peptide and a polymeric modifying group, wherein said G-CSF peptide comprises a structure according to the formula wherein q is 0 or 1; and Sia—PEG has a structure according to the formula: in which n is an integer from 400 to 500, for use in increasing the number of hematopoietic progenitor cells in a subject; 
(c) infuzija koštane srži u primatelja, HR P20130382 T1 Prva smjesa koja sadrži spoj formule (1) 1,1'-[1,4-fenilen-bis-(metilen)-bis-1,4,8,11-tetraazaciklotetradekan (AMD3100); 1 druga smjesa koja sadrži peptid koji je kovalentni konjugat između G-CSF peptida 1 polimerne modificirajuće skupine, gdje taj G-CSF peptid ima strukturu prema formuli
The amorphous zirconia ZrOx(OH)4-2x, is precipitated by adding 10 M KOH until a pH of 13.5 is reached. 
Amorfna cirkonija (ZrO,(OH)42,) je taložena dodavanjem 10 M KOH do dostizanja pH od 13.5.
A method of claim 1 for the treatment of idiopathic dystonia or dystonia caused by the use of cocaine. 
Farmaceutska smjesa iz zahtjeva 6 ili zahtjeva 7, naznačena time, što se koristi za liječenje Parkinsonove bolesti.
The halogen-substituted lower alkyl groups include the lower alkyl groups as mentioned above having 1 to 7, preferably 1 to 3, halogen atoms as a substituent(s). 
(A1lb) fenoksi-supstituiranu skupinu niži alkil s halogen-supstituiranom skupinom (skupinama) niži alkil kao supstituentom (s) na fenilnoj skupini,
The method of claim 1, wherein the therapeutically effective amount of the compound of claim 1 is from about 0.1 mg/dose to about 5 g/dose. 
Spoj za uporabu kako je zatraženo u zahtjevu 30 naznačen time da terapeutski učinkovita količina spoja prema zahtjevu 1 je od oko 0.1 mg/dozi do oko 5 g/dozi.
According to some embodiments of the present invention, the water-free silane-based liquid may be applied to the at least one profiled surface in an amount of less than 150 g/m2, and more than 10 g/m2. 
Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što se bezvodna tekućina na bazi silana primjenjuje na najmanje jednu profiliranu površinu u količini manjoj od 150 g/m', više od 10 g/m'.
It may also be favourable, if the flat upper guiding surface of the chamber runs into the lower curved guiding surface with a steeper guiding surface section. 
Naprava u skladu s bilo kojim od patentnih zahtjeva 7-10, naznačena time što ravna gornja površina za vođenje (24a) komore (18) prema donjoj zakrivljenoj površini za vođenje strmijim dijelom površine za vođenjo.
A process for the production of expandable vinyl aromatic polymer granulate by an extrusion or a suspension process, the process comprising the addition of a geopolymer; a combination of a geopolymer with an athermanous additive; or 
3. = Postupak za proizvodnju ekspandirajućeg granulata vinil aromatskog polimera postupkom ekstruzije ili suspenzije, naznačen time što postupak obuhvaća dodavanje geopolimernog kompozita dobivenog iz geopolimera i koji sadrži aditiv koji ne prenosi infracrveno zračenje.
The utility connector module may include, for example without limitation, a motor power connector, a resolver connector, a fluid inlet, and a fluid outlet. Desirably, each of these connectors can be secured to a mating connector simultaneously. 
Modul priključaka može npr. uključiti, među ostalim, priključak za napajanje motora, glavni priključak, mjesto za ulaz fluida i mjesto za izlaz fluida (npr. ulja za podmazivanje).
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) cyprodinil. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, le kao komponentu (B) ciprodinil.
The composition of any one of the previous claims which is a sterile composition. 
Sastav u skladu s bilo kojim od prethodnih zahtjeva ozračen u rasponu od 5-25 KGy.
The method of claim 43, wherein the base is added and the amount of base added is more than sufficient to fully neutralize the polycarboxylic acid polymer. 
Postupak za koji se traži zaštita patentom u patentnom zahtjevu 13, ili patentnom zahtjevu 14, pri čemu je dodana količina baze više nego dovoljna da potpuno neutralizira polimer polikarboksilne kiseline.
An assembly, comprising a container according to claim 1, engaged with a closure having a plurality of members on an interior surface thereof arranged to abut the flat surfaces of at least some of the first retention members. 
Sklop, koji obuhvaća: posudu (100) prema bilo kojem prethodnom patentnom zahtjevu spregnutom sa zatvaračem (400) koji ima više elemenata na svojoj unutranjoj površini postavljenih da se podudaraju s čelnim površinama barem nekih od zadržnih elemenata (140).
The immunoconjugate of claim 10 comprising an antibody (Ab), and an auristatin or maytansinoid drug moiety (D) wherein the cysteine engineered antibody is attached through one or more free cysteine amino acids by a linker moiety (L) to D; the compound having Formula I: 
Imunokonjugat prema zahtjevu 10, naznačen time, da obuhvaća protutijelo (Ab), i dio molekule auristatina ili majtanzinoida (D), pri čemu je cisteinski modificirano protutijelo priključeno na D, preko jedne ili više slobodnih cisteinskih aminokiselina, pomoću vezne skupine (L); gdje spoj ima formulu I:
The heteromolecular metal complex according to claim 1, wherein organic molecule A is a humic acid that has been treated with an amine in a step subsequent to formation of the heteromolecular complex. 
Heteromolekularni metalni kompleksi (kelati) otkriveni u zahtjevima 1 do 7, naznačeni time što je molekula A huminska kiselina koja je bila tretirana sa aminom u koraku koji je uslijedio nakon tvorbe heteronuklearnog kompleksa.
The method of claim 1 wherein the sample is rendered single stranded and said predefined subsequences are captured under hybridizing conditions by a number of single-stranded probes which are catalogued by bar coding or which are physically separated on an array. 
Postupak prema zahtjevu 1, naznačen time da je uzorak načinjen jednolančanim i navedene prethodno definirane podsekvence su vezane pod hibridizirajućim uvjetima s brojnim jednolančanim probama koje su katalogizirane štapićastim kodom ili koje su fizički odvojene u nizu. 10.
A pharmaceutical combination, comprising: a first active comprising the compound, or a pharmaceutically acceptable salt thereof, according to any of Claims 1 to 12 and a second active selected from osmotic agents, ENaC blockers, anti-inflammatory agents, bronchodilatory agents, antihistamine agents, anti-tussive agents, antibiotic agents and DNase drug substances, wherein the first and second actives may be in the same or different pharmaceutical composition. 
-amino-5,6-bis-trifluorometil-piridin-2-karboksilna kiselina-((R)-3,3,3-trifluoro-2-hidroksi-2-metil-propil)-amid; ili njegova farmaceutski prihvatljiva sol, te drugo djelatno sredstvo odabrano od sljedećih: osmotski agens, ENaC-blokatori, protuupalna sredstva, bronhodilatorna sredstva, antihistaminici, antitusivna sredstva, antibiotici i ljekovite DNase-supstance, pri čemu prvo i drugo djelatno sredstvo mogu biti u istom farmaceutskom sastavu ili u različitim farmaceutskim sastavima.
The method of claim 1 further comprising the step of adding a pH adjustment agent to the mixture of steps (a), (b,) (c) or (d) to adjust the pH to approximately 7.5-9.0. 
Postupak prema patentnom zahtjevu 41 ili 42, naznačen time što sadrži i dodatne korake: b1) dodavanje jednog ili više puferiranih sredstava; 1 b2) dodavanje sredstva za podešavanje pH vrijednosti da bi se pH podesila do približno 7.5-9.0.